| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
AGILE-3 Score for the diagnosis of advanced fibrosis and for predicting liver-related events in nonalcoholic fatty liver disease
|
Pennisi, G.
|
|
|
54 |
S1 |
p. S17-S18
|
article
|
| 2 |
A.I.S.F. 2022: Abstracts evaluation procedure
|
|
|
|
54 |
S1 |
p. S62
|
article
|
| 3 |
A new high-throughput HBV integration sequencing approach shows that mitochondrial DNA is frequently targeted by virus integration in liver cells with active HBV replication
|
Giosa, D.
|
|
|
54 |
S1 |
p. S8-S9
|
article
|
| 4 |
A non-invasive tests for the assessment of advanced liver fibrosis in patients with non-alcoholic fatty liver disease: a cross sectional study in a third referral centre
|
Viganò, M.
|
|
|
54 |
S1 |
p. S32
|
article
|
| 5 |
Arterial hypertension in cirrhotic patients is associated with older age and protects against liver decompensation independently of the etiology of the liver disease
|
Pitrone, C.
|
|
|
54 |
S1 |
p. S48-S49
|
article
|
| 6 |
Bacterial infection as a predisposing factor for the development of portal vein thrombosis in cirrhotic patients: a prospective study
|
De Marco, L.
|
|
|
54 |
S1 |
p. S43-S44
|
article
|
| 7 |
Biomarkers, imaging and safety in resmetirom 52 week non-cirrhotic NASH phase 3 clinical trial, completed open-label arm of maestro-NAFLD-1
|
Harrison, Dr. S.A.
|
|
|
54 |
S1 |
p. S48
|
article
|
| 8 |
Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study
|
Wedemeyer, H.
|
|
|
54 |
S1 |
p. S24-S25
|
article
|
| 9 |
Clinical and prognostic characterization of the patterns of decompensation of liver cirrhosis
|
Tonon, M.
|
|
|
54 |
S1 |
p. S1-S2
|
article
|
| 10 |
Clinical features of patients with new onset of autoimmune hepatitis following SARS-CoV-2 vaccination
|
Rigamonti, C.
|
|
|
54 |
S1 |
p. S48
|
article
|
| 11 |
Coagulation imbalance is associated with hepatic fibrosis and vascular complications in patients with type2 diabetes and NAFLD
|
Lombardi, R.
|
|
|
54 |
S1 |
p. S38
|
article
|
| 12 |
Comparative performance analysis between manual and automatic RNA extraction to quantify HDV RNA by RoboGene 2.0 kit in untreated and bulevirtide-treated HDV patients
|
Degasperi, E.
|
|
|
54 |
S1 |
p. S39-S40
|
article
|
| 13 |
Comparison of severity of liver damage and metabolic alterations in patients with NAFLD attending the hepatology clinic over the last three decades
|
Colavolpe, L.
|
|
|
54 |
S1 |
p. S39
|
article
|
| 14 |
Comparison of therapeutic outcomes of liver resection and transarterial chemoembolization in multifocal HCC: a propensity score-matched analysis
|
Campani, C.
|
|
|
54 |
S1 |
p. S60
|
article
|
| 15 |
Controlled attenuation parameter in primary biliary cholangitis: a cross-sectional analysis
|
Degasperi, E.
|
|
|
54 |
S1 |
p. S35
|
article
|
| 16 |
CONUT score predicts early morbidity after liver transplantation: a collaborative study
|
Spoletini, G.
|
|
|
54 |
S1 |
p. S57
|
article
|
| 17 |
Cross-talk between MerTK-expressing stromal cells and cholangiocarcinoma
|
Pastore, M.
|
|
|
54 |
S1 |
p. S5-S6
|
article
|
| 18 |
De-novo occurrence of portal vein thrombosis in patients with HCV-related cirrhosis after sustained virological response: medium to long term observations from the ongoing PITER cohort
|
Kondili, L.A.
|
|
|
54 |
S1 |
p. S49
|
article
|
| 19 |
Development and validation of a deep learning model for the prediction of hepatocellular cancer recurrence after transplantation: an international study
|
Lai, Q.
|
|
|
54 |
S1 |
p. S9
|
article
|
| 20 |
Diabetes and number of metabolic risk factors influence liver disease severity in patients with non-alcoholic fatty liver disease
|
D'Ambrosio, R.
|
|
|
54 |
S1 |
p. S35-S36
|
article
|
| 21 |
Diagnostic and prognostic role of urinary Neutrophil Gelatinase-associated Lipocalin in patients with cirrhosis and acute kidney injury
|
Gambino, C.
|
|
|
54 |
S1 |
p. S8
|
article
|
| 22 |
Different immunological microenvironment in patients with different cirrhosis etiology and hepatocellular carcinoma
|
Dalbeni, A.
|
|
|
54 |
S1 |
p. S3-S4
|
article
|
| 23 |
Divergent patterns of hbv-rna and hbcrag levels in untreated chronic hepatitis delta: a large european cross-sectional study
|
Degasperi, E.
|
|
|
54 |
S1 |
p. S38-S39
|
article
|
| 24 |
Early post-liver transplant HCV eradication with sofosbuvir/velpatasvir/voxilaprevir in NS5A-inhibitor experienced patients
|
Saracco, M.
|
|
|
54 |
S1 |
p. S20
|
article
|
| 25 |
Editorial Board
|
|
|
|
54 |
S1 |
p. i-ii
|
article
|
| 26 |
Effectiveness and safety of bulevirtide monotherapy 2 mg/die in hdv patients with compensated cirrhosis and clinically significant portal hypertension
|
Degasperi, E.
|
|
|
54 |
S1 |
p. S15
|
article
|
| 27 |
Efficacy and safety of pangenotypic DAAs for chronic HCV infection: real-world data from the RESIST-HCV cohort
|
Salomone, F.
|
|
|
54 |
S1 |
p. S55-S56
|
article
|
| 28 |
Epidemiological, virological and clinical profile of HBsAg positive individuals in Italian hospital settings: interim results of the HBV/HDV PITER cohort
|
Coco, B.
|
|
|
54 |
S1 |
p. S15-S16
|
article
|
| 29 |
Evaluation of allelic frequency and genetic risk score of non-alcoholic fatty liver disease in a population of Southern Italy
|
Motta, B.M.
|
|
|
54 |
S1 |
p. S28-S29
|
article
|
| 30 |
Expert consensus criteria and practical recommendations for pbc care in the covid-19 era and beyond
|
Berenguer, M.
|
|
|
54 |
S1 |
p. S52
|
article
|
| 31 |
Gamma Glutamyl Transferase as a marker of risk of progression to cirrhosis in patients with Primary Biliary Cholangitis
|
Calvaruso, V.
|
|
|
54 |
S1 |
p. S12
|
article
|
| 32 |
Genomic and metabolomic profiles and their correlations with preclinical signs of endothelial dysfunction measured by Peripheral Arterial Tonometry in Non Alcoholic Fatty Liver Disease
|
Masarone, M.
|
|
|
54 |
S1 |
p. S2-S3
|
article
|
| 33 |
Hepatitis Delta in HIV: changes in attitude to testing and disease burden over time
|
Brancaccio, G.
|
|
|
54 |
S1 |
p. S53-S54
|
article
|
| 34 |
Hepatocellular carcinoma with portal vein tumor thrombus: a single-center retrospective analysis
|
Pizzolante, F.
|
|
|
54 |
S1 |
p. S32-S33
|
article
|
| 35 |
High rates of histological findings compatible with porto-sinusoidal vascular liver disease in patients with constantly elevated gamma-glutamyl transferase levels undergoing a liver biopsy
|
Pugliese, N.
|
|
|
54 |
S1 |
p. S43
|
article
|
| 36 |
Humoral, cellular, clinical responses and safety of two doses of SARS-CoV-2 Messenger RNA vaccine in patients with compensated and decompensated cirrhosis: a long-term single center prospective study
|
Iavarone, M.
|
|
|
54 |
S1 |
p. S1
|
article
|
| 37 |
Humoral response to 2-dose BNT162b2 mRNA vaccine for Covid-19 in liver transplant recipients
|
Guarino, M.
|
|
|
54 |
S1 |
p. S19
|
article
|
| 38 |
Hydroxytyrosol and vitamin E combination therapy exerts beneficial effects on NAFLD-related fibrosis
|
Panera, N.
|
|
|
54 |
S1 |
p. S37
|
article
|
| 39 |
Impact of bacterial infections prior liver transplantation on post-transplant outcomes in patients with cirrhosis
|
Incicco, S.
|
|
|
54 |
S1 |
p. S26-S27
|
article
|
| 40 |
Impact of deterioration of lifestyle and PNPLA3 genotype in NALFD patients during COVID-19 lockdown
|
Cinque, F.
|
|
|
54 |
S1 |
p. S40
|
article
|
| 41 |
Impact of polypharmacy and aging on the risk of multiple drug-drug interactions (DDIs) in HCV patients treated with pangenotypic direct-acting antivirals (pDAA)
|
Mangia, A.
|
|
|
54 |
S1 |
p. S44
|
article
|
| 42 |
Impact of renaming NAFLD to MAFLD in a single Italian center
|
Cossiga, V.
|
|
|
54 |
S1 |
p. S23
|
article
|
| 43 |
Implementation of hcv screening in the 1969-1989 birth-cohort undergoing covid-19 vaccination: a pivotal study in Italy
|
D'Ambrosio, R.
|
|
|
54 |
S1 |
p. S36-S37
|
article
|
| 44 |
Incidental findings of anti-mitochondrial antibodies without evidence of Primary Biliary Cholangitis
|
Mauro, S.
|
|
|
54 |
S1 |
p. S31
|
article
|
| 45 |
Increased burden of inherited IRF3 rare genetic variants in Europeans with severe NAFLD
|
Santoro, L.
|
|
|
54 |
S1 |
p. S17
|
article
|
| 46 |
Increased platelet aggregation in decompensated cirrhosis indicates higher risks of further decompensation and liver-related mortality
|
Zanetto, A.
|
|
|
54 |
S1 |
p. S16-S17
|
article
|
| 47 |
Independent determinants of CAP values in healthy individuals with dysmetabolism
|
Bianco, C.
|
|
|
54 |
S1 |
p. S27-S28
|
article
|
| 48 |
Interleukin-6 as a new marker for advanced sarcopenic HCC patients with different cirrhotic aetiology
|
Dalbeni, A.
|
|
|
54 |
S1 |
p. S23-S24
|
article
|
| 49 |
Investigating the effect of gender on liver fibrosis and associated sarcopenia
|
Sayaf, K.
|
|
|
54 |
S1 |
p. S35
|
article
|
| 50 |
Irisin alleviates liver oxidative stress in non-obese, non-diabetic individuals with Non-Alcoholic Fatty Liver Disease
|
Armandi, A.
|
|
|
54 |
S1 |
p. S21
|
article
|
| 51 |
Laboratory diagnosis of HCV for elimination: shadows of the present and lights for the future
|
Costa, E. Garlatti
|
|
|
54 |
S1 |
p. S30
|
article
|
| 52 |
Lifestyle in Primary Biliary Cholangitis: let's pay attention!
|
Cossiga, V.
|
|
|
54 |
S1 |
p. S24
|
article
|
| 53 |
Liver cancer-specific isoform of serine protease inhibitor Kazal for the detection of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
|
Nicolosi, A.
|
|
|
54 |
S1 |
p. S41-S42
|
article
|
| 54 |
Liver cirrhosis in the Emergency Department: a change of paradigm in DAAs era
|
Marrone, G.
|
|
|
54 |
S1 |
p. S57-S58
|
article
|
| 55 |
Liver disease and lipodystrophy: data from an Italian cohort
|
Salvati, A.
|
|
|
54 |
S1 |
p. S42
|
article
|
| 56 |
Liver transplantation for hepatocellular carcinoma:outcome and prognostic factors for recurrence
|
Paon, V.
|
|
|
54 |
S1 |
p. S30-S31
|
article
|
| 57 |
Liver transplantation in HIV infected subjects: a long-term single-center experience
|
Guerrini, G.P.
|
|
|
54 |
S1 |
p. S54
|
article
|
| 58 |
Longevity of seropositivity after anti SARS-CoV-2 vaccination in patients awaiting liver transplant
|
Calleri, A.
|
|
|
54 |
S1 |
p. S22
|
article
|
| 59 |
Long-term albumin administration eases the management of hyponatremia in outpatients with decompensated cirrhosis: data from the ANSWER Trial
|
Zaccherini, G.
|
|
|
54 |
S1 |
p. S40-S41
|
article
|
| 60 |
Long term outcome of elderly recipients after liver transplantation. An Italian multicentric study
|
Melandro, F.
|
|
|
54 |
S1 |
p. S55
|
article
|
| 61 |
Long-term outcomes in pediatric liver transplantation: a single center 20 years- experience
|
Guarino, M.
|
|
|
54 |
S1 |
p. S14-S15
|
article
|
| 62 |
Low hemoglobin predicts early readmission for liver-related causes in patients with cirrhosis discharged after an acute decompensation
|
Pompili, E.
|
|
|
54 |
S1 |
p. S6
|
article
|
| 63 |
Macrophage MerTK promotes a profibrogenic cross-talk with hepatic stellate cells via soluble mediators
|
Pastore, M.
|
|
|
54 |
S1 |
p. S61
|
article
|
| 64 |
Mathematical modeling of cancer cells and vasculature dynamics with serological and imaging biomarkers suggests synergistic effects of TACE and TKIs in HCC patients
|
Colombatto, P.
|
|
|
54 |
S1 |
p. S58
|
article
|
| 65 |
Metabolic dysfunction-associated fatty liver disease and liver fibrosis score in patients with COVID-19 as predictors of adverse clinical outcomes: an artificial intelligent application through machine learning
|
Dalbeni, A.
|
|
|
54 |
S1 |
p. S24
|
article
|
| 66 |
MiRNome profiling of circulating extracellular vesicles in patients with chronic hepatitis delta treated with pegylated interferon alpha
|
Olivero, A.
|
|
|
54 |
S1 |
p. S50
|
article
|
| 67 |
Modeling KLB deficiency by genome editing in hepatocytes: from oxidative stress and inflammation towards enhanced proliferation
|
Meroni, M.
|
|
|
54 |
S1 |
p. S50
|
article
|
| 68 |
Modulation of the cholangiocarcinoma stem-like compartment by monounsaturated fatty acids
|
Lori, G.
|
|
|
54 |
S1 |
p. S60-S61
|
article
|
| 69 |
Morphological features and biological aggressiveness of hepatocellular carcinomas with TERT and TP53 mutations. Preliminary monocentric results on resected patients
|
Vasuri, F.
|
|
|
54 |
S1 |
p. S21
|
article
|
| 70 |
Nash up, virus down: how is changing the waiting list for liver transplantation: a single center experience from Italy
|
Ferrarese, A.
|
|
|
54 |
S1 |
p. S22
|
article
|
| 71 |
Natural history of hepatic encephalopathy (HE) in a tertiary referral centre for hepatology
|
Mangini, C.
|
|
|
54 |
S1 |
p. S6-S7
|
article
|
| 72 |
Non-invasive diagnosis of clinically significant portal hypertension and treatment with non-selective beta-blockers: a new paradigm
|
Dajti, E.
|
|
|
54 |
S1 |
p. S7
|
article
|
| 73 |
Obeticholic acid restores hepatic RECK content in a diet-induced ob/ob mouse model of NASH
|
Cagna, M.
|
|
|
54 |
S1 |
p. S25
|
article
|
| 74 |
Oleuropein prevents liver damage in NAFL mice by modulating copper-catalyzed dicarbonyl stress
|
Santini, S.J.
|
|
|
54 |
S1 |
p. S22-S23
|
article
|
| 75 |
Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis
|
Maira, G.
|
|
|
54 |
S1 |
p. S41
|
article
|
| 76 |
Outcomes of three lines Atezolizumab plus Bevacizumab-based sequential treatment for hepatocellular carcinoma: a simulation model
|
Celsa, C.
|
|
|
54 |
S1 |
p. S52-S53
|
article
|
| 77 |
Patient-derived liver organoids as a 3D in vitro model to studyPNPLA3 I148M role in NAFLD
|
Casirati, E.
|
|
|
54 |
S1 |
p. S33-S34
|
article
|
| 78 |
Persistent biochemical alteration at one year can lead to worse clinical outcomes in autoimmune hepatitis
|
Pezzato, F.
|
|
|
54 |
S1 |
p. S11-S12
|
article
|
| 79 |
Pharmacological interventions effect on liver histology in nonalcoholic steatohepatitis: a network meta-analysis
|
Pennisi, G.
|
|
|
54 |
S1 |
p. S33
|
article
|
| 80 |
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosin-kinase inhibitors: a real-world analysis
|
Stefanini, B.
|
|
|
54 |
S1 |
p. S3
|
article
|
| 81 |
Preclinical evaluations of a novel formulation of PD-L1-targeted liposomal doxorubicin for the treatment of hepatocellular carcinoma
|
Gabbia, D.
|
|
|
54 |
S1 |
p. S29
|
article
|
| 82 |
Predictors of Serious Adverse Event and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis under Obeticholic Acid
|
De Vincentis, A.
|
|
|
54 |
S1 |
p. S12-S13
|
article
|
| 83 |
Predictors of survival of patients with hepatocellular carcinoma in best supportive care
|
Campani, C.
|
|
|
54 |
S1 |
p. S59-S60
|
article
|
| 84 |
Preprocedural prophylaxis with blood products in patients with cirrhosis: results from a survey of the Italian Association for the study of the Liver (AISF)
|
Tosetti, G.
|
|
|
54 |
S1 |
p. S34
|
article
|
| 85 |
Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease: a meta-analysis of observational studies
|
Stupia, R.
|
|
|
54 |
S1 |
p. S42
|
article
|
| 86 |
Prevalence of sarcopenia and cardiovascular alterations in a cohort of non-cirrhotic MAFLD patients
|
Cespiati, A.
|
|
|
54 |
S1 |
p. S37
|
article
|
| 87 |
Prognostic impact of sarcopenia on patients with advanced hepatocellular carcinoma treated with sorafenib
|
Lani, L.
|
|
|
54 |
S1 |
p. S29
|
article
|
| 88 |
Prognostic Models predicting allograft failure at 90 and 365 days after liver transplantation. Call for an international Est to West prospective observational study to guide re-transplantation
|
Avolio, A.
|
|
|
54 |
S1 |
p. S10
|
article
|
| 89 |
Radiomics-based model for outcome prediction in primary sclerosing cholangitis
|
Cristoferi, L.
|
|
|
54 |
S1 |
p. S11
|
article
|
| 90 |
Real-life prevalence of Metabolic Associated Fatty Liver Disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in a tertiary obesity clinic in Italy
|
Ravaioli, F.
|
|
|
54 |
S1 |
p. S47
|
article
|
| 91 |
Rectus femoris ultrasound is an easy bedside tool that identifies sarcopenia and predict a poor clinical course in patients with an acute decompensation of cirrhosis
|
Piano, S.
|
|
|
54 |
S1 |
p. S25-S26
|
article
|
| 92 |
Recurrence of hepatocellular carcinoma and hepatitis delta infection in a liver transplant recipient: a case report
|
Gualandi, N.
|
|
|
54 |
S1 |
p. S53
|
article
|
| 93 |
Referral and outcomes of patients with decompensated alcoholic liver disease: critical issues from our real life experience
|
Costa, E. Garlatti
|
|
|
54 |
S1 |
p. S51
|
article
|
| 94 |
Results from a retrospective, observational, multicentre study of patients with primary biliary cholangitis treated with obeticholic acid in real life in Italy (O-REAL)
|
Alvaro, D.
|
|
|
54 |
S1 |
p. S51-S52
|
article
|
| 95 |
Risk of multiple drug interactions potentially linked to safety in patients receiving pangenotypic direct-acting antivirals for the treatment of hepatitis C
|
Turnes, J.
|
|
|
54 |
S1 |
p. S44-S45
|
article
|
| 96 |
Role of immune activation and senescent profile as prognostic markers for cancer onset in patients undergoing liver transplantation
|
Shalaby, S.
|
|
|
54 |
S1 |
p. S4
|
article
|
| 97 |
Ruling out Varices Needing Treatment with a non-invasive score in patients with compensated HBV cirrhosis
|
Rizzo, G.
|
|
|
54 |
S1 |
p. S58
|
article
|
| 98 |
Sarcopenia predicts ascitic decompensation and mortality independently of portal hypertension status in patients with advanced chronic liver disease outside the liver transplantation setting
|
Dajti, E.
|
|
|
54 |
S1 |
p. S46
|
article
|
| 99 |
SARS-CoV-2 infection in liver transplantation is associated with favorable outcomes: an Italian transplant registry study
|
Rendina, M.
|
|
|
54 |
S1 |
p. S14
|
article
|
| 100 |
Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region
|
Torre, P.
|
|
|
54 |
S1 |
p. S56
|
article
|
| 101 |
SerpinB3/4 expression is associated with poor prognosis in patients with cholangiocarcinoma
|
Martini, A.
|
|
|
54 |
S1 |
p. S28
|
article
|
| 102 |
Serum HBsAg and ddPCR HBV-DNA as predictive parameters of HBsAg loss after nucleo(s)tide analogue (NA) treatment discontinuation in non-cirrhotic patients with Chronic Hepatitis B
|
Guerra, A.F.
|
|
|
54 |
S1 |
p. S34
|
article
|
| 103 |
Steroidomic profiles across the spectrum of liver damage in non-alcoholic fatty liver disease
|
Rosso, C.
|
|
|
54 |
S1 |
p. S5
|
article
|
| 104 |
Surveillance of hepatobiliary cancers in primary sclerosing cholangitis: a preliminary study on the role of PET-MRI
|
Catanzaro, E.
|
|
|
54 |
S1 |
p. S46-S47
|
article
|
| 105 |
Switching tdf treated patients to taf is a safe and effective strategy even in difficult-to-manage elderly patients with hbv-related cirrhosis and significant comorbidities: a real-life prospective study
|
Degasperi, E.
|
|
|
54 |
S1 |
p. S36
|
article
|
| 106 |
The co-presence of PNPLA3, MBOAT7 and TM6SF2 loss-of-functions impairs mitochondrial morphology and number in severe NAFLD patients
|
Longo, M.
|
|
|
54 |
S1 |
p. S5
|
article
|
| 107 |
The forgotten ventricle: right ventricular (RV) evaluation in patients with cirrhosis listed for liver transplantation
|
Giannelli, V.
|
|
|
54 |
S1 |
p. S32
|
article
|
| 108 |
The impact of bacterial infections on cirrhosis complications in a cohort of cirrhotic patients in a northern Italian hospital
|
Mantovani, A.
|
|
|
54 |
S1 |
p. S30
|
article
|
| 109 |
The I148M PNPLA3 variant mitigates Niacin beneficial effects: how the genetic screening in NAFLD patients gains value
|
Paolini, E.
|
|
|
54 |
S1 |
p. S51
|
article
|
| 110 |
The role of histidine-rich glycoprotein in non alcoholic steatohepatitis-related experimental liver carcinogenesis
|
Foglia, B.
|
|
|
54 |
S1 |
p. S38
|
article
|
| 111 |
The synergic effect of non-alcoholic fatty liver disease and hypertension in the development of cardiovascular disease
|
Cattazzo, F.
|
|
|
54 |
S1 |
p. S57
|
article
|
| 112 |
The use of Spleen Stiffness Measurement for the detection of high-risk esophageal varices in patients with portal hypertension
|
Armandi, A.
|
|
|
54 |
S1 |
p. S19-S20
|
article
|
| 113 |
Transarterial chemoembolization for hepatocellular carcinoma in clinical practice: temporal trends and survival outcomes over the last three decades in Italy
|
Pelizzaro, F.
|
|
|
54 |
S1 |
p. S54-S55
|
article
|
| 114 |
Transient receptor potential cation channel subfamily member 7 liver tissue expression in cirrhotic patients correlates with disease severity and hepatocellular damage
|
Parisse, S.
|
|
|
54 |
S1 |
p. S45
|
article
|
| 115 |
Transjugular intra-hepatic portosystemic shunt (TIPS) in elderly patients: preliminary analysis of a multicenter retrospective cohort.
|
Roccarina, D.
|
|
|
54 |
S1 |
p. S7-S8
|
article
|
| 116 |
Trientine tetrahydrochloride versus d-Penicillamine for the management of patients with Wilson Disease: results from the CHELATE trial a year after randomisation
|
Zuin, M.
|
|
|
54 |
S1 |
p. S2
|
article
|
Journal description